Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: RT who wrote (3105)	12/7/1997 9:13:00 PM
From: Andreas Samson	Read Replies (1) \| Respond to of 23519

Where is the Growth for MUSE? I'm a newly-minted VVUS shareholder...from reading the Pfizer thread and this one, there appears to be a sense of looming omnipotence with respect to the release of Viagra. (i.e MUSE will be seriously threatened) Whether this is a matter of perception or soon to be an economic fact is difficult to say....in the market there really isn't a distinction. I used to own a little one-trick pony called Auspex Systems (ASPX) which posted steady 30% gains in the UNIX file server market. Top-rated product -- terrible stock, mired in the $9-12 level for over a year. The problem was they didn't have a NT product....and even though UNIX still has a much larger percentage of the data storage market, all the Growth is taking place (or perceived to be) in the NT area. Now I'm sitting here on my 600 shares that aren't responding to FDA news, product approval or buy recommendations and I'm asking myself where is the growth for MUSE? If the serious ED cases are resorting so surgery/injections, and the milder/psychological cases are going to Viagra what is the MUSE market going to be? How big is it? Have Viagra and MUSE ever been tested head-to-head?